title: Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients.
abstract: The influence of BK virus nephropathy (BKVN) in pancreas after kidney (PAK) transplantation is unclear. A retrospective analysis of PAK transplants performed at our center was conducted to determine the impact of BKVN. Among 40 PAK transplants performed using sequential immunosuppression, four patients developed BKVN, as defined by a >20% rise in serum creatinine and BK viremia (BK plasma load >4 log copies/mL), at a median of 19 months following PAK. In all four patients, treatment of BKVN consisted of reduction in tacrolimus, cessation of mycophenolate mofetil, and introduction of leflunomide. With this approach, two patients experienced improvement or stabilization of renal function. The remaining two patients progressed to dialysis dependence despite treatment. Plasma BK load < or =5 log copies/mL was associated with graft preservation. Gender, age, delay between transplants, cumulative Thymoglobulin dose, and type of kidney donor were not associated with BK virus infection. Pancreas graft rejection or dysfunction was not observed with the above immunosuppression modification. Mean amylase and lipase > or =6 months following BKVN treatment remained normal. BKVN is an important cause of kidney allograft loss in PAK patients. Screening and early treatment of BKVN may enable preservation of kidney and pancreas grafts.
authors.affiliation: Kidney Transplant Program, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Duclos
authors.forename: V
authors.initials: V
authors.lastname: Krishnamurthi
authors.forename: M
authors.initials: M
authors.lastname: Lard
authors.forename: E
authors.initials: E
authors.lastname: Poggio
authors.forename: M
authors.initials: M
authors.lastname: Kleeman
authors.forename: C
authors.initials: C
authors.lastname: Winans
authors.forename: R
authors.initials: R
authors.lastname: Fatica
authors.forename: S
authors.initials: S
authors.lastname: Nurko
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001739:BK Virus; D004359:Drug Therapy, Combination; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007555:Isoxazoles / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D000077339:Leflunomide; D016347:Medical Records Systems, Computerized; D010182:Pancreatic Diseases / Q000453:epidemiology / Q000821:virology*; D027601:Polyomavirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D011183:Postoperative Complications / Q000453:epidemiology / Q000821:virology*; D015995:Prevalence; D012189:Retrospective Studies; D014412:Tumor Virus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000998:Antiviral Agents; D007555:Isoxazoles; D000077339:Leflunomide